GMED vs HUMA
GMED: Globus Medical develops spine implants, orthopedic devices, and regenerative tissue biologics to treat musculoskeletal disorders through direct surgeon engagement and hospital partnerships. HUMA: Humacyte engineers acellular tissue-based blood vessels (ATEVs) for vascular access and other applications, with its lead product Symvess in late-stage clinical development.
Side-by-side fundamentals
| Metric | GMED | HUMA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $78.25 | $0.674 | |
| Market cap as of 2026-07-30 | $10.9B | $168M | |
| P/E as of 2026-07-30 | 18.63 | n/a | |
| PEG as of 2026-07-30 | 0.08 | n/a | |
| Net margin as of 2026-07-30 | +18.9% | -3494.6% | GMED higher |
| Gross margin as of 2026-07-30 | +67.9% | -563.6% | GMED higher |
| Operating margin as of 2026-07-30 | +21.0% | -6205.7% | GMED higher |
| ROE as of 2026-07-30 | +13.0% | -1278.9% | GMED higher |
| ROA as of 2026-07-30 | +11.3% | -85.4% | GMED higher |
| Debt / equity as of 2026-07-30 | 0.00 | 5.67 | GMED lower |
| Revenue growth (YoY) as of 2026-07-30 | +23.5% | +231.7% | HUMA higher |
| Revenue CAGR (3y) SEC XBRL | +42.2% | n/a | |
| Beta as of 2026-07-30 | 0.96 | 2.57 | |
| 1-year return as of 2026-07-27 close | +43.6% | -73.4% | GMED higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.